Floatz logo

Zimberelimab

Prostatic Cancer, Castration-Resistant

Arcus Biosciences, Inc.monoclonal_antibodyPhase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the Prostatic Cancer, Castration-Resistant cohort.

Asset / SponsorPhaseRating
Darolutamide
UNICANCER
Phase 3BB
Enzalutamide
Arcus Biosciences, Inc.
Phase 2B
jsb462
Novartis Pharmaceuticals
Phase 2CCC
VIPIVOTIDE TETRAXETAN
Novartis Pharmaceuticals
Phase 2CCC
Docetaxel
Arcus Biosciences, Inc.
Phase 1/2CCC
Quemliclustat
Arcus Biosciences, Inc.
Phase 1/2CCC
Etrumadenant
Arcus Biosciences, Inc.
Phase 1/2CCC
sxl01
Institut Claudius Regaud
Phase 1CC

Same molecule, other indications

Zimberelimab is also rated in:

Androgen-Resistant Prostatic NeoplasmsDormant
B
Indicative ·
60 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
60 / 100
View asset →
triple-negative breast carcinomaDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →